Overview Financials News + Filings Key Docs Charts Holdings Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results
|
Voyager Therapeutics, Inc. (VYGR)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
10/05/2023 |
4
| PFREUNDSCHUH PETER P. (CFO) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Sold 13,567 shares
@ $6.99, valued at
$94.8k
|
|
10/03/2023 |
144
| Form 144 - Report of proposed sale of securities: |
10/02/2023 |
4
| Fahey Sandell Jacquelyn (Chief Legal Officer) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 61,000 shares
@ $0 |
|
08/16/2023 |
8-K
| Entry into a Material Definitive Agreement, Creation of a Direct Financial Obligation or an Obligation under an Off-Balance S... |
08/03/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
08/03/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
07/11/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
07/11/2023 |
3
| Form 3 - Initial statement of beneficial ownership of securities: |
07/10/2023 |
4
| Carter Todd Alfred (Chief Scientific Officer) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Sold 5,500 shares
@ $10.8, valued at
$59.4k
|
|
07/10/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
07/06/2023 |
144
| Form 144 - Report of proposed sale of securities: |
07/05/2023 |
4
| Carter Todd Alfred (Chief Scientific Officer) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Sold 5,000 shares
@ $11.41, valued at
$57.1k
Exercised 5,000 options to buy
@ $2.85, valued at
$14.3k
|
|
06/30/2023 |
144
| Form 144 - Report of proposed sale of securities: |
06/07/2023 |
4
| PIERCE GLENN (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| MACKEY CATHERINE J (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| Vitale Nancy (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| Onyia Jude (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| Higgins Michael J (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| Colon Grace (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| GERAGHTY JAMES A (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| SCANGOS GEORGE A (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
4
| Hyman Steven (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 22,000 options to buy
@ $12.57, valued at
$276.5k
|
|
06/07/2023 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
05/11/2023 |
4
| SCANGOS GEORGE A (Director) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Granted 44,000 options to buy
@ $10.76, valued at
$473.4k
|
|
05/11/2023 |
3
| SCANGOS GEORGE A (Director) has filed a Form 3 on Voyager Therapeutics, Inc. |
05/09/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
05/09/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
05/09/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data |
05/09/2023 |
8-K
| Appointed a new director |
04/27/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
04/27/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
04/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
04/05/2023 |
4
| Sandrock Alfred (President and CEO) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Sold 7,437 shares
@ $7.83, valued at
$58.2k
|
|
04/05/2023 |
4
| Swartz Robin (COO) has filed a Form 4 on Voyager Therapeutics, Inc.
Txns:
| Sold 1,259 shares
@ $7.83, valued at
$9.9k
|
|
|
|
|